-
Safety Aspects of Herb Interactions: Current Understanding and Future Prospects Curr. Drug Metab. (IF 2.3) Pub Date : 2024-03-14 Subhajit Hazra, Preet Amol Singh
Background: The use of herbal medicines is on the rise throughout the world due to their perceived safety profile. However, incidences of herb-drug, herb-herb and herb-food interactions considering safety aspects have opened new arenas for discussion. Objective: The current study aims to provide comprehensive insights into the various types of herb interactions, the mechanisms involved, their assessment
-
Altitude effect on Propofol Pharmacokinetics in Rats Curr. Drug Metab. (IF 2.3) Pub Date : 2024-03-12 Lijun Li, Xuejun Wang, Sheng Wang, Li Wen, Haopeng Zhang
Background:: Propofol is an intravenous agent for clinical anesthesia. As the influence of the hypobaric- hypoxic environment (Qinghai-Tibetan region, altitude: 2800-4300 m, PaO2: 15.1-12.4 kPa) on the metabolism of Propofol is complex, the research results on the metabolic characteristics of Propofol in high- -altitude areas remain unclear. This study aimed to investigate the pharmacokinetic characteristics
-
Safety Issues of Herb-Warfarin Interactions Curr. Drug Metab. (IF 2.3) Pub Date : 2024-03-11 Subhajit Hazra, Preet Amol Singh, Neha Bajwa
: Warfarin is a popular anticoagulant with high global demand. However, studies have underlined serious safety issues when warfarin is consumed concomitantly with herbs or its formulations. This review aimed to highlight the mechanisms behind herb-warfarin interactions while laying special emphasis on its PKPD interactions and evidence on Herb-Warfarin Interaction (HWI) with regards to three different
-
A Phase I Clinical Study of the Pharmacokinetics and Safety of Prusogliptin Tablets in Subjects with Mild to Moderate Hepatic Insufficiency and Normal Liver Function Curr. Drug Metab. (IF 2.3) Pub Date : 2024-03-08 Huiting Zhang, Yicong Bian, Weifeng Zhao, Liyan Miao, Hua Zhang, Juanjuan Cui, Xiaofang Zhang, Xueyuan Zhang, Wen Cai
Background: Prusogliptin is a potent and selective DPP-4 inhibitor. In different animal models, Prusogliptin showed potential efficacy in the treatment of type 2 diabetes. However, the knowledge of its pharmacokinetics and safety in patients with liver dysfunction is limited. Objectives: The present study evaluated the pharmacokinetics and safety of Prusogliptin in subjects with mild or moderate hepatic
-
Comparative Analysis of Machine Learning Algorithms Evaluating the Single Nucleotide Polymorphisms of Metabolizing Enzymes with Clinical Outcomes Following Intravenous Paracetamol in Preterm Neonates with Patent Ductus Arteriosus Curr. Drug Metab. (IF 2.3) Pub Date : 2024-03-06 Kannan Sridharan, George Priya Doss C, Hephzibah Cathryn R, Thirumal Kumar D, Muna Al Jufairi
Aims: Pharmacogenomics has been identified to play a crucial role in determining drug response. The present study aimed to identify significant genetic predictor variables influencing the therapeutic effect of paracetamol for new indications in preterm neonates. Background: Paracetamol has recently been preferred as a first-line drug for managing Patent Ductus Arteriosus (PDA) in preterm neonates.
-
The Role of CYPs and Transporters in the Biotransformation and Transport of the Anti-hepatitis C Antiviral Agents Asunaprevir, Daclatasvir, and Beclabuvir: Impact of Liver Disease, Race and Drug-drug Interactions on Safety and Efficacy Curr. Drug Metab. (IF 2.3) Pub Date : 2024-03-05 Michael Murray
: Asunaprevir, daclatasvir, and beclabuvir are direct-acting antiviral agents used in the treatment of patients infected with hepatitis C genotype 1b. This article reviews the biotransformation and disposition of these drugs in relation to the safety and efficacy of therapy. CYP3A4 and 3A5 catalyze the oxidative biotransformation of the drugs, while P-glycoprotein mediates their efflux from tissues
-
A Combination of Magnoflorine and Spinosin Improves the Antidepressant effects on CUMS Mouse Model Curr. Drug Metab. (IF 2.3) Pub Date : 2024-02-28 Fenghe Bi, Zhihui Wang, Yijing Guo, Menglin Xia, Xuehui Zhu, Wei Qiao
Background: Depression is a common neuropsychiatric disease. As a famous traditional Chinese medicine with significant anti-depressive and sleep-promoting effects, Ziziphi Spinosae Semen (ZSS) has attracted the attention of many researchers. Although it is well known that Magnoflorine (MAG) and Spinosin (SPI) were the main active components isolated from ZSS, there is a lack of research on the combined
-
Recent Advances in Hepatic Metabolic Regulation by the Nuclear Factor Rev-erbɑ Curr. Drug Metab. (IF 2.3) Pub Date : 2024-02-27 Qi Zhang, Yutong Chen, Jingqi Li, Haishan Xia, Yongbin Tong, Yuyu Liu
: Rev-erbɑ (NR1D1) is a nuclear receptor superfamily member that plays a vital role in mammalian molecular clocks and metabolism. Rev-erbɑ can regulate the metabolism of drugs and the body's glucose metabolism, lipid metabolism, and adipogenesis. It is even one of the important regulatory factors regulating the occurrence of metabolic diseases (e.g., diabetes, fatty liver). Metabolic enzymes mediate
-
Effect of High Altitude Environment on Pharmacokinetic and Pharmacodynamic of Warfarin in Rats Curr. Drug Metab. (IF 2.3) Pub Date : 2024-02-27 Xiaojing Zhang, Hongfang Mu, Yan Zhong, Rong Wang, Wenbin Li
Background: High altitude environment affects the pharmacokinetic (PK) parameters of drugs and the PK parameters are an important theoretical basis for guiding the rational clinical use of drugs. Warfarin is an oral anticoagulant of the coumarin class commonly used in clinical practice, but it has a narrow therapeutic window and wide individual variation. However, the effect of high altitude environment
-
Effect of Dexketoprofen on the Disposition Kinetics of Moxifloxacin in Plasma and Lung in Male and Female Rats Curr. Drug Metab. (IF 2.3) Pub Date : 2024-01-23 Teslime Erdogan, Halis Oguz, Orhan Corum
Background:: The simultaneous use of NSAIDs and antibiotics is recommended for bacterial dis-eases in human and veterinary medicine. Moxifloxacin (MFX) and dexketoprofen (DEX) can be used simul-taneously in bacterial infections. However, there are no studies on how the simultaneous use of DEX affects the pharmacokinetics of MFX in rats. Objectives:: The aim of this study was to determine the effect
-
Inhibitory Effects of Tricyclic Antidepressants on Human Liver Microsomal Morphine Glucuronidation: Application of IVIVE to Predict Potential Drug-Drug Interactions in Humans Curr. Drug Metab. (IF 2.3) Pub Date : 2024-01-09 Verawan Uchaipichat
Background:: Tricyclic antidepressants (TCAs) are commonly co-administered with morphine as an adjuvant analgesic. Nevertheless, there remains a lack of information concerning metabolic drug-drug in-teractions (DDIs) resulting from TCA inhibition on morphine glucuronidation. Objective:: This study aimed to (i) examine the inhibitory effects of TCAs (viz., amitriptyline, clomipramine, imipramine, and
-
Drug-Protein Interactions Prediction Models Using Feature Selection and Classification Techniques Curr. Drug Metab. (IF 2.3) Pub Date : 2024-01-09 T. Idhaya, A. Suruliandi, S. P. Raja
Background:: Drug-Protein Interaction (DPI) identification is crucial in drug discovery. The high dimensionality of drug and protein features poses challenges for accurate interaction prediction, necessitating the use of computational techniques. Docking-based methods rely on 3D structures, while ligand-based methods have limitations such as reliance on known ligands and neglecting protein structure
-
Nutritional Therapy Strategies Targeting Tumor Energy Metabolism Curr. Drug Metab. (IF 2.3) Pub Date : 2023-12-28 Taojia Chen, Haining Yu
Cancer is the second leading cause of mortality worldwide. The heightened nutrient uptake, particularly glucose, and elevated glycolysis observed in rapidly proliferating tumor cells highlight the potential targeting of energy metabolism pathways for the treatment of cancer. Numerous studies and clinical trials have demonstrated the efficacy of nutritional therapy in mitigating the adverse effects
-
Reassessment of Radiation Exposure From Bone Scintigraphy Curr. Drug Metab. (IF 2.3) Pub Date : 2023-12-20 Handan Tanyildizi-Kökkülünk, Ahmet Murat Şenişik, Mahmut Yüksel
Aim: This study was aimed to re-determine the radiation dose rate emitted from the patients who underwent bone scintigraphy. Material and Methods: A mean of 20.87±2.54 mCi 99mTc-MDP was injected into patients. A GM counter was used to measure dose rates in 3 different periods, at intervals of 25, 50, 100, 150, and 200 cm from the patient's anterior for head, thorax, abdomen, and pelvis levels. Measurements
-
The Impacts and Changes Related to the Cancer Drug Resistance Mechanism Curr. Drug Metab. (IF 2.3) Pub Date : 2023-12-20 Prachi varshney, Vishal Sharma, Devdhar Yadav, Yogesh Kumar, Amit Singh, Naga Rani Kagithala, Pramod Kumar Sharma, Omji Porwal, Neeraj Kumar Fuloria, Pradeep Kumar Sharma, Ashok Kumar Gupta, Koteswara Rao GSN
Background: Cancer drug resistance remains a difficult barrier to effective treatment, necessitating a thorough understanding of its multi-layered mechanism. Objective: This study aims to comprehensively explore the diverse mechanisms of cancer drug resistance, assess the evolution of resistance detection methods, and identify strategies for overcoming this challenge. The evolution of resistance detection
-
Comparative Pharmacokinetics of Intravenous Enrofloxacin in One- Six- And Twelve-Month-Old Sheep Curr. Drug Metab. (IF 2.3) Pub Date : 2023-12-20 Devran Coskun, Orhan Corum, Duygu Durna Corum, Kamil Uney
Background: Enrofloxacin (ENR) is a fluoroquinolone antibiotic approved for use in sheep of all ages. The body composition and metabolic capability change with age. These changes may alter the pharmacokinetics of drugs and thus their effect. Therefore, the pharmacokinetics of drugs need to be established in target- age animals. Objective: To determine the pharmacokinetics of ENR and its active metabolite
-
Theoretical Evaluation of Oleocanthal Reactive Centers Curr. Drug Metab. (IF 2.3) Pub Date : 2023-12-19 Mohammad Hossein Asgarshamsi, Mehrdad Mohammadpour Dehkordi, Seyed Mohamad Reza Nazifi, Krzysztof K. Zborowski
Background: Decarboxymethyl ligstroside aglycone (oleocanthal) is an essential component of olive oil. It is therefore interesting to study its metabolism in the human body. In order to find the best possible starting point for this metabolism, a theoretical study was carried out using DFT calculations and docking studies. Methods: The DFT, B3LYP/6-311++G** and the PCM solvation model calculations
-
Pharmacokinetics, Mass Balance, Tissue Distribution and Metabolism of [14C]101BHG-D01, a Novel Muscarinic Receptor Antagonist, in Rats Curr. Drug Metab. (IF 2.3) Pub Date : 2023-12-08 Huaye Gao, Cheng Yang, Wenhui Hu, Juefang Ding, Xingxing Diao, Yuandong Zheng, Chang Shu, Li Ding
Background: 101BHG-D01, a novel long-acting and selective muscarinic receptor antagonist for the treatment of chronic obstructive pulmonary disease (COPD), is undergoing Phase Ib clinical trial in patients and has shown its potential efficacy. Its preparation method and medical use thereof have been patented in the United States (Patent No.US9751875B2). Objective: In this study, the pharmacokinetics
-
In Silico Tools to Thaw the Complexity of the Data: Revolutionizing Drug Research in Drug Metabolism, Pharmacokinetics and Toxicity Prediction Curr. Drug Metab. (IF 2.3) Pub Date : 2023-12-06 Hema Sree Kommalapati, Pushpa Pilli, Vijaya Madhyanapu Golla, Nehal Bhatt, Gananadhamu samanthula
In silico tool is the flourishing pathway for Researchers and budding chemists to strain the analytical data in a snapshot. Traditionally, drug research has heavily relied on labor-intensive experiments, often limited by time, cost, and ethical constraints. In silico tools have paved the way for more efficient and cost-effective drug development processes. By employing advanced computational algorithms
-
The Impact of Certain Pharmacogenetic Differences on the Metabolism of Antiretroviral Drugs Used in A Black South African Population Curr. Drug Metab. (IF 2.3) Pub Date : 2023-11-24 Riaan Reay, Michelle Viljoen, Malie Rheeders
Background: Genetic polymorphism of drug-metabolising enzymes and transporters may influence the effect and toxicity of antiretroviral drugs. Objectives: To determine and compare the minimum allele frequency of 20 single nucleotide polymorphisms (SNPs) with possible involvement in the metabolism of the antiretroviral drugs with other populations. To investigate the influence of these variants on Reverse
-
Evaluation of Supervised Machine Learning Algorithms and Computational Structural Validation of Single Nucleotide Polymorphisms Related to Acute Liver Injury with Paracetamol Curr. Drug Metab. (IF 2.3) Pub Date : 2023-11-03 Kannan Sridharan, Ambritha Balasundaram, Thirumal Kumar D, George Priya Doss C
Aims: To identify single nucleotide polymorphisms (SNPs) of paracetamol-metabolizing enzymes that can predict acute liver injury. Background: Paracetamol is a commonly administered analgesic/antipyretic in critically ill and chronic renal failure patients and several SNPs influence the therapeutic and toxic effects. Objective: To evaluate the role of machine learning algorithms (MLAs) and bioinformatics
-
Crocin Ameliorates Diabetic Nephropathy through Regulating Metabolism, CYP4A11/PPARγ, and TGF-β/Smad Pathways in Mice Curr. Drug Metab. (IF 2.3) Pub Date : 2023-11-02 Wei Chen, Jinhao Su, Yubin Liu, Tianmei Gao, Xiaohui Ji, Hanzhou Li, Huajun Li, Yuansong Wang, Hui Zhang, Shuquan Lv
Introduction: Crocin is one of the main components of Crocus sativus L. and can alleviate oxidative stress and inflammation in diabetic nephropathy (DN). However, the specific mechanism by which crocin treats DN still needs to be further elucidated. Method: In the present study, a mouse model of DN was first established to investigate the therapeutic effect of crocin on DN mice. Subsequently, non-targeted
-
Differential Pharmacokinetic Interplay of Atorvastatin on Lacosamide and Levetiracetam on Experimental Convulsions in Mice Curr. Drug Metab. (IF 2.3) Pub Date : 2023-10-25 Jayaraman Rajangam, Arun Prasath Lakshmanan, Narahari N. Palei, Karthikeyan Elumalai, Muddukrishnaiah Kotakonda, R. Prakash, P Latha
Background: The beneficial effects of statins, other than their hypocholesterolemia role, have been well documented, however, their use as an adjuvant drug with other antiseizure drugs, in the treatment of epilepsy is poorly understood. Objective: This study aimed to investigate the symbiotic effect of ATOR along with either lacosamide (LACO) or levetiracetam (LEVE) on experimentally induced epilepsy
-
Nrf2 Regulates the Expression of CYP2D6 by Inhibiting the Activity of Krüppel-Like Factor 9 (KLF9) Curr. Drug Metab. (IF 2.3) Pub Date : 2023-10-24 Ferbian Milas Siswanto, Maria Dara Novi Handayani, Rita Dewi Firmasyah, Ami Oguro, Susumu Imaoka
Aims: The aim of the present study is to gain insight into the biology of Parkinson’s disease (PD) and cancer to drive translational advances enabling more effective prevention and/or potential treatments. Background: The expression of Cytochrome P450 2D6 (CYP2D6) is correlated with various diseases such as PD and cancer; therefore, exploring its regulatory mechanism at transcriptional levels is of
-
Comprehensive Investigation of the Influence of High-Altitude Hypoxia on Clopidogrel Metabolism and Gut Microbiota Curr. Drug Metab. (IF 2.3) Pub Date : 2023-10-11 Juanhong Zhang, Yuemei Sun, Jiaxin He, Guofan Wu, Rong Wang, Junmin Zhang
Background: The amount of metabolites converted into active metabolites is correspondingly reduced since only more than 50% of clopidogrel is absorbed. Objective: Exploring the effect of gut microbiota altered by altitude hypoxia on the pre-absorption metabolism of clopidogrel. Methods: In vitro and in vivo experiments were conducted to analyze the metabolism of clopidogrel through LCMS/ MS, while
-
Corrigendum: Intracellular Delivery: Exploiting Viral Membrane Topic Peptide Curr. Drug Metab. (IF 2.3) Pub Date : 2023-10-05 Stefania Galdiero, Mariateresa Vitiello, Annarita Falanga, Marco Cantisani, Novella Incoronato, Massimiliano Galdiero
The authors declare that after the publication of the article, it was noticed that two citations were inadvertently omitted. The references have now been included as [74b] and [74c]: [74] (b) Vitiello, M.; Galdiero, M.; Galdiero, M. Inhibition of Viral-Induced Membrane Fusion by Peptides. Protein Pep. Lett., 2009, 16(7), 786-793. (c) Galdiero, S.; Falanga, A.; Vitiello, M.; D'Isanto, M.; Cantisani
-
Artificial Intelligence in Drug Formulation and Development: Applications and Future Prospects Curr. Drug Metab. (IF 2.3) Pub Date : 2023-09-28 Noorain, Varsha Srivastava, Bushra Parveen, Rabea Parveen
Artificial Intelligence (AI) has emerged as a powerful tool in various domains, and the field of drug formulation and development is no exception. This review article aims to provide an overview of the applications of AI in drug formulation and development and explore its future prospects. The article begins by introducing the fundamental concepts of AI, including machine learning, deep learning, and
-
Pharmacokinetics and Tissue Distribution of Isovitexin-2''-O-β-D-glucopyranoside (IVG) in Sprague-Dawley Rats Curr. Drug Metab. (IF 2.3) Pub Date : 2023-09-28 Xiaotong Zhao, Leilei Fang, Tan Yang, Yanqing Zhang, Junbo Xie
Background: Isovitexin-2
-
The Influence of Atorvastatin, Amlodipine and Ethoxidol on Ubiquinol and Ubiquinone Endogenous Plasma Concentrations in Patients with Chronic Heart Failure Curr. Drug Metab. (IF 2.3) Pub Date : 2023-09-22 V.I. Zozina, S.N. Kondratenko, E.V. Shikh, L.M. Krasnykh, E.S. Melnikov, V.G. Kukes
Background: Coenzyme Q10 is a key component of the mitochondrial respiratory chain and a fat-soluble endogenous antioxidant performing many vital functions in the human body. Many researchers studied the plasma concentrations of ubiquinol, ubiquinone, total CoQ10 and the redox state (ubiquinol/ubiquinone ratio) of CoQ10 in healthy volunteers. However, these parameters in the plasma of patients with
-
Which can Predict the Outcome of Antidepressants: Metabolic Genes or Pharmacodynamic Genes? Curr. Drug Metab. (IF 2.3) Pub Date : 2023-09-11 Nan Zheng, Menxi Niu, Yan-nan Zang, Hong Yan Zhuang, Fei Jia, Shuang Bao, Shan-shan Liu
: Drug therapy is the primary modality for depression; however, its outcome is often unpredictable, ranging from beneficial effects to serious adverse effects. Genetic variations in drug metabolizing enzymes and pharmacodynamic molecules are responsible for a considerable proportion of interindividual differences in the effectiveness and toxicity of antidepressants. For the improvement in the use of
-
Preclinical Pharmacokinetics and CYP Modulation Activity of Chebulinic Acid: A Potent Molecule Against Metabolic Disease Curr. Drug Metab. (IF 2.3) Pub Date : 2023-09-11 Arpon Biswas, Sarvesh Kumar Verma, Shiv Kumar, Tripti Mishra, Mukesh Kumar, Abhijit Deb Choudhury, Sristi Agrawal, Sachin Nashik Sanap, Amol Chhatrapati Bisen, Anjali Mishra, Tadigoppula Narender, Rabi Sankar Bhatta
Background: Chebulinic acid (CA) is an active constituent of Terminalia chebula fruits with therapeutic potential against multiple metabolic diseases, including dementia, benign prostate hyperplasia, and osteoporosis. Objective: The present work intends to explore the preclinical pharmacokinetics, including the absolute bioavailability of CA and its influence on the gene expression of cytochrome P450
-
In vivo Metabolism of Nifurtimox and the Drug-Drug Interaction Potential Including its Major Metabolites Curr. Drug Metab. (IF 2.3) Pub Date : 2023-09-08 Simone I. Schulz, Dieter Lang, Gabriele Schmuck, Michael Gerisch, Michaela Bairlein, Robert Fricke, Heino Stass
Background: Nifurtimox is an effective treatment for patients with Chagas disease, but knowledge of its biotransformation and excretion is limited. Objective: This study aimed to better understand the fate of oral nifurtimox in vivo. Methods: We investigated the exposure and excretion pathways of [14C]-labeled nifurtimox and its metabolites in rats. We then quantified the prominent metabolites and
-
Herbal Medicines as Adjuvants for the Treatment of Chemotherapy-Induced Diarrhea Curr. Drug Metab. (IF 2.3) Pub Date : 2023-08-31 Zicong Zheng, Songpol Srinual, Jie Chen, Li Li, Ting Du, Ming Hu, Rongjin Sun, Song Gao
Background: Chemotherapeutic drugs used in cancer treatment often result in gastrointestinal toxicity, notably diarrhea, impacting patients’ quality of life. Complementary and Alternative Medicine (CAM) has garnered increasing interest as an alternative to conventional approaches as a potential solution for managing chemotherapyinduced diarrhea (CID). Objective: To summarize current research focusing
-
Molecular Insights into the Mechanism of Modulatory Effects of Proton Pump Inhibitors on P-glycoprotein Mediated Drug Transport of Palbociclib and Ribociclib Curr. Drug Metab. (IF 2.3) Pub Date : 2023-08-31 Mrunal Pradeep Desai, Prajakta Harish Patil, Sai Krishna Anand Vullendula, Sumit Birangal, G. Gautham Shenoy, Mahadev Rao, Swapnil Jayant Dengale, Krishnamurthy Bhat, Jagadish Puralae Channabasavaiah
Background: Palbociclib and ribociclib are substrates of efflux transporter P-glycoprotein which plays a key role in absorption and transport of these drugs. Proton pump inhibitors, when co-administered with them are known to show inhibitory effect on P-glycoprotein. Objective: Therefore, this study aims to investigate the role of proton pump inhibitors in inhibition of P-glycoprotein mediated efflux
-
Comparative Analysis of Pharmacokinetics and Metabolites of Three Main Terpenoids before and after Compatibility of Frankincense and Myrrh in Rats by UHPLC-MS Curr. Drug Metab. (IF 2.3) Pub Date : 2023-08-31 Ruo-ying Fan, Ru-Meng Gao, Jia-Shang Li, Shu-Lan Su, Er-Xin Shang, Da-Wei Qian, Jin-Ao Duan
Background: 3-acetyl-11-keto-beta-boswellic acid (AKBA) and 11-keto-boswellic acid (KBA) are the main active components of frankincense as pentacyclic triterpenoids, which are designated by the European Pharmacopoeia 8.0 as the quality standard for the evaluation of Indian frankincense, 2-methoxy-8,12-epoxygermacra- 1(10),7,11-trien-6-one (MCS134) is a non-volatile sesquiterpene compound in myrrh.
-
A Mini-review on Recent Strategies and Applications of Nanomedicines to Combat Antimicrobial Resistance Curr. Drug Metab. (IF 2.3) Pub Date : 2023-08-31 Kanak Chahar, Yash Sharma, Preeti Patel, Vivek Asati, Balak Das Kurmi
One of the key factors contributing to mortality and morbidity globally is infectious ailments. According to recent statistics from WHO, amplified antimicrobial resistance occurrence among bacteria signifies the utmost threat to global public health. Bacteria have developed various strategies to resist antimicrobials, including enzymatic inactivation of antibiotics, drug efflux, modifications of the
-
Covalent Modification of Proteins by Osthole Reactive Metabolites using Proteomic Approaches Curr. Drug Metab. (IF 2.3) Pub Date : 2023-08-31 Yue Zhuo, Huiling Chen, Chenchen Liu, Yida Zhang, Jiansong Fang, Meng Li, Zhendong Wang, Qiyao Jiang, Liangwen Yu, Huafeng Pan, Qi Wang
Background: Osthole (OST) is a bioactive natural coumarin derived from the plant Cnidium monnieri(L.) Cusson fruit (She Chuang Zi), which has various pharmacological and biological activities. OST contains an α,β- unsaturated lactone, which is an electrophilic group that tends to be metabolized into reactive metabolites (RMs). Then, RMs are able to covalently modify nucleophilic amino acid (AA) residues
-
Worldwide Prevalence of Polypharmacy: A Systematic Review Curr. Drug Metab. (IF 2.3) Pub Date : 2023-08-31 Beatriz Dias Januário, Natália Silva Mafra, Humberto de Souza Silva, Isabella Monteiro Carvalho, Ana Luiza Sobreira Sena, Ana Paula Gomes Soares Pereira, Newton Santos de Faria Júnior, Helton Oliveira Campos
Introduction: The present study has compiled the prevalence of polypharmacy worldwide and assessed the prevalence of polypharmacy in different populations, including community-dwelling individuals, hospitalized patients, and institutionalized patients. Methods: This systematic review was conducted and reported according to the guidelines outlined in the Preferred Reporting Items for Systematic Reviews
-
Synthesis and Biomedical Applications of DNA Hydrogel Curr. Drug Metab. (IF 2.3) Pub Date : 2023-07-31 Qi Zhang, Shiyu Lin, Junyu Shi
Deoxyribonucleic acid (DNA), as a natural polymer material, carries almost all the genetic information and is recognized as one of the most intelligent natural polymers. In the past 20 years, there have been many exciting advances in the synthesis of hydrogels using DNA as the main backbone or cross-linking agent. Different methods, such as physical entanglement and chemical cross-linking, have been
-
Computational Structural Validation of CYP2C9 Mutations and Evaluation of Machine Learning Algorithms in Predicting the Therapeutic Outcomes of Warfarin Curr. Drug Metab. (IF 2.3) Pub Date : 2023-07-24 Kannan Sridharan, Thirumal Kumar D, Suchetha Manikandan, Gaurav Prasanna, Lalitha Guruswamy, Rashed Al Banna, George Priya Doss C
Aim: The study aimed to identify the key pharmacogenetic variable influencing the therapeutic outcomes of warfarin using machine learning algorithms and bioinformatics tools. Background: Warfarin, a commonly used anticoagulant drug, is influenced by cytochrome P450 (CYP) enzymes, particularly CYP2C9. MLAs have been identified to have great potential in personalized therapy. Objective: The purpose of
-
Pharmacokinetics, Mass Balance, Tissue Distribution, and Metabolism of [3H]Catalpol in Rats: the Main Bioactive Component of Rehmannia glutinosa for the Treatment of Ischemic Stroke Curr. Drug Metab. (IF 2.3) Pub Date : 2023-07-17 Xinyu Ge, Yuandong Zheng, Yifei He, Chong Chen, Chen Yang, Saiwei Lu, Zhenyu Xuan, Dafang Zhong, Xingxing Diao
Background: Catalpol, one of the main bioactive components isolated from Rehmannia glutinosa, was developed by Suzhou Youseen for the treatment of ischemic stroke; however, preclinical information about its absorption, distribution, metabolism, and excretion (ADME) in animals is inadequate. Objective: This study aimed to illuminate the pharmacokinetics (PK), mass balance (MB), tissue distribution (TD)
-
The Application of Nucleic Acid Nanomaterials in the Treatment of Mitochondrial Dysfunction Curr. Drug Metab. (IF 2.3) Pub Date : 2023-07-13 Lan Yao, Qing Hai, Tao Zhang
Mitochondrial dysfunction is considered highly related to the development and progression of diseases, including cancer, metabolism disturbance, and neurodegeneration. Traditional pharmacological approach for mitochondrial dysfunction treatment has off-target and dose-dependent side effects, which leads to the emergence of mitochondrial gene therapy by regulating coding or noncoding genes by using
-
Interaction of Intestinal Microbiota with Medications Curr. Drug Metab. (IF 2.3) Pub Date : 2023-07-07 Mengchen Liu, Jiaqiang Xu, Qianna Jin, Yunqiao Li
Introduction: It is well known that the response to and metabolism of the drugs entering the human body varies widely across individuals. One of the reasons is that such interpersonal differences may be related to gut microbes. On one hand, drugs or xenobiotics entering the human body may affect the composition of the gut microbiome; on the other hand, the gut microbiota may alter the absorption, distribution
-
Structure of the Blood Brain Barrier and its Role in the Transporters for the Movement of Substrates across the Barriers Curr. Drug Metab. (IF 2.3) Pub Date : 2023-06-22 Ankul Singh S, Chitra Vellapandian
For the brain to operate normally and to develop with structural integrity in addition to neuronal function, blood-brain barrier present in brain capillaries serves as a vital barrier mechanism. In addition to the transport barrier created by membranes, transporters, and vesicular processes, the structure and function of the BBB are summarised. The physical barrier is created by endothelial tight junctions
-
Global Xenobiotic Profiling of Rat Plasma Using Untargeted Metabolomics and Background Subtraction-Based Approaches: Method Evaluation and Comparison Curr. Drug Metab. (IF 2.3) Pub Date : 2023-06-21 Xiaojuan Jiang, Simian Chen, Mingshe Zhu, Caisheng Wu
Background: Global xenobiotic profiling (GXP) is to detect and structurally characterize all xenobiotics in biological samples using mainly liquid chromatography-high resolution mass spectrometry (LC-HRMS) based methods. GXP is highly needed in drug metabolism study, food safety testing, forensic chemical analysis, and exposome research. For detecting known or predictable xenobiotics, targeted LC-HRMS
-
Recent Advances in Novel Recombinant RNAs for Studying Post-transcriptional Gene Regulation in Drug Metabolism and Disposition Curr. Drug Metab. (IF 2.3) Pub Date : 2023-06-21 Mei-Juan Tu, Ai-Ming Yu
Drug-metabolizing enzymes and transporters are major determinants of the absorption, disposition, metabolism, and excretion (ADME) of drugs, and changes in ADME gene expression or function may alter the pharmacokinetics/ pharmacodynamics (PK/PD) and further influence drug safety and therapeutic outcomes. ADME gene functions are controlled by diverse factors, such as genetic polymorphism, transcriptional
-
Metabolism Pathways of Major Therapeutics for Treating Monkeypox Mono- and Co-infection with Human Immunodeficient Virus or SARS-CoV-2 Curr. Drug Metab. (IF 2.3) Pub Date : 2023-06-19 Daisy Yan, Bingfang Yan
Monkeypox is a zoonotic viral disease and remains endemic in tropical regions of Central and West Africa. Since May of 2022, cases of monkeypox have soared and spread worldwide. Confirmed cases have shown no travel history to the endemic regions as seen in the past. The World Health Organization declared monkeypox a global public health emergency in July 2022, and the United States government followed
-
Methods to Improve the Stability of Nucleic Acid-Based Nanomaterials Curr. Drug Metab. (IF 2.3) Pub Date : 2023-06-15 Xueping Xie, Wenjuan Ma, Yuxi Zhan, Qifeng Zhang, Chaowei Wang, Huiyong Zhu
Nucleic acid strands can be synthesized into various nucleic acid-based nanomaterials (NANs) through strict base pairing. The self-assembled NANs are programmable, intelligent, biocompatible, non-immunogenic, and non-cytotoxic. With the rapid development of nanotechnology, the application of NANs in the biomedical fields, such as drug delivery and biological sensing, has attracted wide attention. However
-
Comparative Pharmacokinetics of Scoparone and its Metabolite Scopoletin in Normal and ANIT-induced Intrahepatic Cholestatic Rats Curr. Drug Metab. (IF 2.3) Pub Date : 2023-06-12 Qiru Tian, Huan Jin, Xiaokui Huo, Yupu Zhao, Wenhui Wu, Lei Xu, Yinan Wang, Xiaobo Yang, Chengpeng Sun, Sa Deng, Xiaohong Shu
Background: Scoparone, the principal natural active ingredient of Artemisia capillaries (Yin Chen), can effectively treat cholestatic diseases, but the pharmacokinetic properties of scoparone are rarely studied in intrahepatic cholestatic rats. Objective: A sensitive and rapid LC-MS/MS method was established to detect scoparone and its metabolite of scopoletin in rat plasma and then compare their plasma
-
The Metabolic Pathways and Products of Ten Aconitum Alkaloids in Sanwujiao Pills from Eight Organs of Mice by UHPLC-Q-TOF-MS/MS Curr. Drug Metab. (IF 2.3) Pub Date : 2023-06-12 Wen-Han Pei, Yu-Feng Huang, Ying Xie, Yuan Qu, Fan He, Hua Zhou
Background: Sanwujiao pill (SWJP) is a Chinese herbal preparation widely used in China. It is an essential medicine for treating rheumatism and blood stasis. However, its safety in clinical use has always been the focus of patients because it contains toxic herbs of Aconitum carmichaelii Debx. and A. vilmorinianum Kom. Objective: To further reveal the pharmaceutical and toxic effect substances and
-
State-of-the-art Application of Artificial Intelligence to Transporter-centered Functional and Pharmaceutical Research Curr. Drug Metab. (IF 2.3) Pub Date : 2023-06-08 Jiayi Yin, Nanxin You, Fengcheng Li, Mingkun Lu, Su Zeng, Feng Zhu
Protein transporters not only have essential functions in regulating the transport of endogenous substrates and remote communication between organs and organisms, but they also play a vital role in drug absorption, distribution, and excretion and are recognized as major determinants of drug safety and efficacy. Understanding transporter function is important for drug development and clarifying disease
-
Physiologically Based Pharmacokinetic Model for Older Adults and Its Application in Geriatric Drug Research Curr. Drug Metab. (IF 2.3) Pub Date : 2023-06-05 Xinyi Wu, Jie En Valerie Sia, Min Hai, Xuan Lai, Haiyan Li, Cheng Cui, Dongyang Liu
Drug-related adverse events are higher in older patients than in non-older patients, increasing the risk of medication and reducing compliance. Aging is accompanied by a decline in physiological functions and metabolic weakening. Most tissues and organs undergo anatomical and physiological changes that may affect the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of drugs. Clinical trials
-
LC-Q-TOF/MS-based Fragmentation Behavior Study and In vitro Metabolites Identification of Nine Benzodiazepines Curr. Drug Metab. (IF 2.3) Pub Date : 2023-05-19 Shuhan Zhou, Xiaoting Song, Pengkai Fang, Jingyi Xu, Siqi Liu, Tian Zheng, Guoping Wu, Liang Wu
Background: Benzodiazepines (BZDs) are compounds that contain one diazepine ring and two benzene rings, and are widely used to treat central nervous system diseases. However, drug abuse and BZDs' illegal addition may affect normal life and even lead to grave social harm. As BZDs may be metabolized and eliminated quickly, it is of great theoretical and practical significance to clarify their metabolic
-
DNA-based Nanomaterials in the Immunotherapy Curr. Drug Metab. (IF 2.3) Pub Date : 2023-05-19 Hongxiao Huang, Shaojingya Gao, Xiaoxiao Cai
Background: Nucleic acid is a genetic material that shows great potential in a variety of biological applications. With the help of nanotechnology, the fabrication of DNA-based nanomaterials has emerged. From genetic DNA to non-genetic functional DNA, from single-layer and flat structure to multi-layer and complex structure, and from two-dimensional to three-dimensional structure, DNA-based nanomaterials
-
Application of Nucleic Acid Nanomaterials in the Treatment of Endocrine and Metabolic Diseases Curr. Drug Metab. (IF 2.3) Pub Date : 2023-05-12 Qiang Zhu, Yuping Xie, Ting Fu, Chengji Shi, Long Bai, Lin Liu, Jingang Xiao
Endocrine and metabolic diseases are the most prevalent chronic diseases globally, posing the greatest hazard to human health. Although various medications are applied in treating endocrine and metabolic illnesses, numerous obstacles exist to overcome. Nucleic acid nanomaterials are novel materials synthesized and engineered in the laboratory. In this case, Nucleic acids are employed as non-biological
-
Integrated 16S rRNA Sequencing and Untargeted Metabolomics Analysis to Reveal the Protective Mechanisms of Polygonatum sibiricum Polysaccharide on Type 2 Diabetes Mellitus Model Rats Curr. Drug Metab. (IF 2.3) Pub Date : 2023-05-12 Hui Zhang, Hanzhou Li, Baochao Pan, Shufang Zhang, Xiuhai Su, Wenjuan Sun, Tianyu Zhang, Zhaiyi Zhang, Shuquan Lv, Huantian Cui
Background: Polygonatum sibiricum polysaccharide (PSP) can improve insulin resistance and inhibit oxidative stress. However, the detailed anti-diabetic mechanism of PSP is still poorly defined. Methods: In this study, the anti-diabetic, anti-inflammatory and anti-oxidative effects of PSP were evaluated on a type 2 diabetes mellitus (T2DM) rat model. Furthermore, we investigated the changes in gut microbiota
-
Folate Targeting Peptide Conjugates for Inflammatory Response Suppression Curr. Drug Metab. (IF 2.3) Pub Date : 2023-05-10 Elizabeth Ruff, Scott Poh
Background and Objective: Protein kinases known as mitogen-activated protein kinases (MAPKs) are responsible for regulating a wide variety of physiological cell responses by generating and release of inflammatory mediators. Suppressing these inflammatory mediators can be utilized to control the propagation of inflammation. During the course of this research, we created folate-targeted MK2 inhibitor
-
Factors Influencing ADME properties of therapeutic antisense oligonucleotides: physicochemical characteristics and beyond Curr. Drug Metab. (IF 2.3) Pub Date : 2023-04-20 Rongrong Jiang, Raku Shinkyo, Shirin Hooshfar, Marsha Rebecca Eno, Cassandra Yun, Estevan Sonego Zimmermann
: Therapeutic antisense oligonucleotides (ASOs) represent a diverse array of chemically modified singlestranded deoxyribonucleotides that work complementarily to affect their mRNA targets. They vastly differ from conventional small molecules. These newly developed therapeutic ASOs possess unique absorption, distribution, metabolism, and excretion (ADME) processes that ultimately determine their pharmacokinetic
-
Pharmacokinetic Drug-Drug Interactions Involving Antiretroviral Agents: an Update Curr. Drug Metab. (IF 2.3) Pub Date : 2023-04-20 Zheng Yuan, Yingfei Li, Xin Yu, Lifeng Zhao
: Antiretroviral therapy is the recognized treatment for human immunodeficiency virus (HIV) infection involving several antiviral agents. Even though highly active antiretroviral therapy has been proven to be very effective in suppressing HIV replication, the antiretroviral drugs, belonging to different pharmacological classes, present quite complex pharmacokinetic properties such as extensive drug
-
Research Progress of Epigenetic Modification on the Regulation of Transporters Under Hypoxia Curr. Drug Metab. (IF 2.3) Pub Date : 2023-04-17 Yilan Zhao, Hongfang Mu, Anpeng Zhao, Shilan Feng, Rong Wang
Epigenetic modification refers to the heritable changes caused by chromosomal changes without changing the DNA sequence. Epigenetics runs through the entire growth and differentiation process of the body, which causes varied diseases. Hypoxia is a physiological astate of lowered partial oxygen partial pressure that affects cell and tissue function. Transporters are proteins that maintain a normal and